Scholar Rock
SRRK
Performance
About Scholar Rock
Scholar Rock is a Cambridge, Massachusetts-based biopharmaceutical company focused on discovering, developing, and delivering therapies that address diseases rooted in protein growth factors. The company uses a science-first approach to selectively target growth factor biology to treat serious conditions, with a pipeline spanning neuromuscular, cardiometabolic, immuno-oncology, fibrotic, and hematology indications. Scholar Rock emphasizes translating bold science into therapies that improve patients’ lives and offers information for patients, healthcare professionals, and investors through its newsroom and resources.
Recent News
Scholar Rock’s Apitegromab BLA Resubmission Boosts Stock 11% in Pre‑Market
Regulatory Actions for April 1, 2026
Published FDA Rejections Point to Manufacturing, Data Gaps as Key Stumbling Blocks
Muscle Growth Drug ‘Could Reduce Loss of Lean Tissue’ when Using Slimming Jabs
Biohaven Looks to Obesity to Bounce Back From Run of Clinical and Regulatory Failures
Novo Cuts 400 Jobs in Indiana as Scholar Rock Refiles Drug Linked to the Factory